Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

OliX Pharmaceuticals, Inc.

올릭스226950KOSDAQSector: Pharma & Biotech
₩105,5002.03%Market cap ₩2.22TAs of Sep 1, 2026 close · updated once daily
Market cap
₩2.22T
#36 in KOSDAQ
Loss
PER not computable
14.58x
Sector median 1.59x
0.0%
Sector median 0.0%
C
Grade C48.1 ptsBottom 44% of 2,523 graded stocksPreviously BMethodology v2.0
Financial strength
53.1/100
Growth momentum
65.5/100
Price attractiveness
31.5/100
Shareholder Return
37.5/100

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCCurrentDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band C with a total score of 48.1 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩58,800High ₩207,000
Latest close
Price change by period
1W
5.00%
1M
11.20%
3M
38.90%
1Y
79.40%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

53.1/100
How much debt does it carry relative to equity?
30.2%
Sector median 51.6%
Sector lowhighTop 29.4% in sector
Can it cover what's due within a year?
660.5%
Sector median 191.7%
Sector lowhighTop 20.4% in sector
How much of revenue becomes profit?
-204.4%
Sector median -2.4%
Sector lowhighBottom 19.1% in sector
How much did it earn on its own capital?
-10.5%
Sector median -4.5%
Sector lowhighBottom 43.1% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

65.5/100
How much did revenue grow in a year?
158.3%
Sector median 6.4%
Sector lowhighTop 5.7% in sector
Has it grown steadily over three years?
16.3%
Sector median 4.9%
Sector lowhighTop 17.3% in sector
Did core profits grow in a year?
3.1%
Sector median 3.6%
Sector lowhighBottom 48.7% in sector
Are core profits higher than three years ago?
-34.0%
Sector median 3.5%
Sector lowhighBottom 36.3% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

31.5/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.1x · 58% loss-making
Sector lowhighTop 47.2% in sector
Is the price expensive relative to book value?
14.58x
Sector median 1.59x
Sector lowhighBottom 10.3% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 1, 2026

Of 9 items: 5 met · 4 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩15.7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩15.9B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
-39.5% → -22.1%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
-₩15.9B vs -₩15.7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
74.1% → 23.2%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
51.7% → 660.5%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
18,459,573 → 20,189,883
Operating margin up
Whether operating income over revenue rose from the prior year.
Met
-544.6% → -204.4%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Met
0.06x → 0.21x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026C

Methodology version change (v2.0 applied)

Jul 15, 2026B→CVersion v1.1

Methodology version change (v1.1 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

Private CB/BW issuance resolutions (past 36 months)

2 private-placement convertible bond (CB) / bond-with-warrants (BW) issuance resolutions were disclosed in the past 36 months (latest filing 2025-03-07). View filing ↗

CB with conversion-price adjustment clause (past 36 months)

2 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2025-03-07). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-01

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Paid-in capital increaseJul 8, 2026Source ↗
Paid-in capital increaseJun 29, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →